Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

8.64
Delayed Data
As of Dec 02
 -0.03 / -0.35%
Today’s Change
3.61
Today|||52-Week Range
9.23
+40.95%
Year-to-Date
'Yuge' Sector Rotation Will Continue
Dec 01 / TheStreet.com - Paid Partner Content
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
Nov 30 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close8.67
Today’s open8.63
Day’s range8.27 - 8.82
Volume1,040,128
Average volume (3 months)1,338,159
Market cap$605.2M
Dividend yield--
Data as of 4:00pm ET, 12/02/2016

Growth & Valuation

Earnings growth (last year)-1,033.33%
Earnings growth (this year)+112.50%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)-80.45%
P/E ratio54.0
Price/Sales49.26
Price/Book6.68

Competitors

 Today’s
change
Today’s
% change
HRTXHeron Therapeutics I...+0.20+1.32%
KERXKeryx Biopharmaceuti...+0.15+2.72%
ENTAEnanta Pharmaceutica...+0.31+0.99%
CLLSCellectis SA+0.60+3.66%
Data as of 4:00pm ET, 12/02/2016

Financials

Next reporting dateMarch 16, 2017
EPS forecast (this quarter)-$0.19
Annual revenue (last year)$8.7M
Annual profit (last year)-$39.1M
Net profit margin-450.81%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark Robert Baker
Vice President-
Operations
Meryl J. Longval
Corporate headquarters
Tarrytown, New York

Forecasts


Search for Jobs